Patrys (PAB) Stock Price, News & Analysis

Company Overview

Patrys Limited, together with its subsidiaries, develops and commercializes antibody technologies for the treatment of cancer in Australia. Its lead technology is Deoxymab 3E10, a DNA damage-repair antibody that penetrates cell nuclei. The company focuses on developing PAT-DX1, an antibody fragment for the treatment of primary and secondary brain cancer. In addition, it is developing PAT-DX3, a full-sized antibody that has DNA-binding and DNA damage repair blocking properties of PAT-DX1 used for tissue distribution, pharmacokinetic profile, etc.; and PAT-DX1-NP, a product based on the targeted delivery of nanoparticles carrying therapeutic payloads to the inside of cancer cells. Patrys Limited was incorporated in 2006 and is based in Melbourne, Australia.

Key Stats

• Today's Range: N/A
• 50-Day Range: N/A
• 52-Week Range: N/A
• Volume: 250,000 shs
• Average Volume: N/A
• Market Capitalization: $5.14 million
• P/E Ratio: N/A
• Dividend Yield: 8.82%
• Price Target: N/A
• Consensus Rating: N/A

PAB Stock Analysis - Frequently Asked Questions

How were Patrys' earnings last quarter?

Patrys Limited (ASX:PAB) announced its earnings results on Wednesday, February, 20th. The company reported $0.00 EPS for the quarter. Patrys had a negative trailing twelve-month return on equity of 83.38% and a negative net margin of 253.85%.

What other stocks do shareholders of Patrys own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Patrys investors own include Eagers Automotive (APE), Allied Gaming & Entertainment (AGAE), Avino Silver & Gold Mines (ASM), Avino Silver & Gold Mines (ASM), Academy Sports and Outdoors (ASO), Berkeley Energia (BKY) and Global X Cloud Computing ETF (CLOU).

Company Calendar

• Last Earnings: 2/20/2019
• Today: 5/02/2025

Industry, Sector and Symbol

• Stock Exchange: ASX
• Sector: Medical
• Industry: Biotechnology
• Sub-Industry: N/A
• Current Symbol: ASX:PAB
• CIK: N/A
• Web: www.patrys.com
• Phone: 61 3 9692 7222
• Fax: N/A
• Employees: N/A
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-3,540,000.00
• Net Margins: -253.85%
• Pretax Margin: N/A
• Return on Equity: -83.38%
• Return on Assets: -37.86%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 5.53
• Quick Ratio: 24.38

Sales & Book Value

• Annual Sales: $1.39 million
• Price / Sales: 0.00
• Cash Flow: N/A
• Price / Cash Flow: 2.40
• Book Value: A$0.00 per share
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 2,060,000,000
• Free Float: N/A
• Market Cap: $5.14 million
• Optionable: Not Optionable
• Beta: 0.42